September 10, 2025HemaSphereOpen Access

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

View Full Paper

Ask AI

Bookmark

Authors

COCorentin OrvainCentre National de la Recherche Scientifique STSuzanne TavitianCentre Hospitalier Universitaire de Toulouse CMClémence MediavillaCentre Hospitalier Universitaire de Bordeaux

Discussion

Member takes

Implication

Multicentric cohort analysis highlights outcomes with azacitidine and combinations in myeloproliferative neoplasms, suggesting improved survival with combination therapies.

Key Points

Patients treated with azacitidine combined with ruxolitinib had an overall survival of 18.00 months, markedly better than other combinations or monotherapy.
The median overall survival across 149 patients with accelerated and blast-phase myeloproliferative neoplasms was 8.04 months, emphasizing treatment limitations.
Patients with complex karyotype or TP53 mutations had poorer survival, indicating a need for targeted therapies in this vulnerable group.
Combination therapies involving azacitidine showed nonsignificantly higher overall survival when compared to monotherapy, pointing to potential benefits.

Cite This Study

Orvain et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64785f7c https://doi.org/10.1002/hem3.70202

View Full Paper

Ask AI

Bookmark

Implication

Multicentric cohort analysis highlights outcomes with azacitidine and combinations in myeloproliferative neoplasms, suggesting improved survival with combination therapies.

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider